BIO101 in Obesity

a unique program to preserve muscle during weight loss

a unique program to preserve muscle during weight loss

The Medical Need:

Obesity affects over 1 billion people globally, and 96% of obese patients report mobility issues.

Recent Anti-obesity medications have revolutionized obesity management, delivering unprecedented weight loss results. However, they come with a critical challenge:  significant loss of lean muscle mass accompanies fat loss.

There is currently no approved therapy to preserve muscle mass during obesity management.

Preclinical results:

Four weeks combination treatment of BIO101 with a GLP-1 receptor agonist on diet-induced obese mice showed promising results:

  • Improved animal mobility and grip strength when compared to untreated groups
  • Combination of drugs compensates for muscle contractility alterations

OBA Phase 2 Design:

The clinical study will focus on muscle quality in obesity management.

  • Targeted Indication: adjunctive treatment to GLP-1 receptor agonists to reduce the muscle mass loss associated with GLP-1 and dieting in overweight and obese adult patients
  • Targeted population: 164 obese patients with one or more weight-related sequelae, who will start treatment with semaglutide (a GLP-1 agonist)
  • Primary Endpoint: Muscle strength as measured by knee extension (dynamometry)